Hello everyone, and welcome to the Catalent, Inc. Q1 fiscal year 2023 earnings conference call. My name is Daisy, and I'll be coordinating your call today. If you would like to register a question ready for the Q&A session, please press Star followed by one on your telephone keypad. I would now like to hand the call over to your host, Paul Surdez, Vice President of Investor Relations, to begin. Paul, please go ahead. Thanks, Daisy. Good morning, everyone, and thank you all for joining us today to review Catalent's Q1 2023 financial results. Joining me on the call today are Alessandro Maselli, President and Chief Executive Officer, and Tom Castellano, Senior Vice President and Chief Financial Officer. Please see our agenda for today's call on slide 2 of our supplemental presentation, which is available on our investor relations website at investor.catalent.com. During our call today, management will make forward-looking statements and refer to GAAP and non-GAAP financial measures. It is possible that actual results could differ from management's expectations. We refer you to slide 3 for more detail on forward-looking statements. Slides 4 and 5 discuss Catalent's use of non-GAAP financial measures and our just-issued earnings release provides reconciliations to the most directly comparable GAAP measures. Please also refer to Catalent's Form 10-Q that will be filed with the SEC today for an additional information on the risks and uncertainties that may bear on our operating results, performance, and financial condition. Now, I would like to turn the call over to Alessandro Maselli, whose opening remarks will begin on slide 6 of the presentation. Thanks, Paul, and welcome everyone to the call. We started the year with solid results and positive momentum as a strong constant currency growth in excess of 25% in non-COVID related revenues helped offset headwinds from lower COVID product demand, inflation, and unfavorable foreign exchange translation. First, I would like to highlight that the results in the Q1 were initially expected to include $54 million of revenues and adjusted EBITDA related to the resolution of take-or-pay contracts for fill and finish of the Janssen viral vector COVID-19 vaccine at our Bloomington and Ann Arbor sites. We agreed to an early termination of the contracts, which reflects the changing demand patterns for the COVID-19 vaccines in order to accommodate this long-standing and significant customer as we set a new and strengthened framework for our growing partnership. We received the agreed payments on these settled contracts in October and now expect that recognition of the related revenue will occur in the Q2 of this fiscal year. The change in the expected timing of this revenue recognition was not a notable factor when we updated our fiscal 2023 guidance, which I will cover in a few moments. Turning to our Q1 results, as shown on slide 6, without including our A&S revenues or adjusted EBITDA, the $54 million just discussed, we reported the Q1 revenue of $1.022 billion, flat on a reported basis or a 4% increase in constant currency compared to the Q1 of fiscal 2022. When we also exclude acquisitions and divestitures, organic revenue declined 1% measured in constant currency. Our Q1 adjusted EBITDA of $187 million declined 26% as reported, or 24% on a constant currency basis compared to the Q1 of fiscal 2022. When excluding acquisition and divestitures, the decline was 28%, measured in constant currency. Turning to the business, as noted on slide 7, Q1 non-COVID organic cost and currency growth was more than 20%. The growth in our non-COVID business was driven by our cell and gene therapy offerings in our biologic segment, as well as our clinical development services in our pharma and consumer health segment, which is starting to benefit from commercial synergies under the new organizational structure. As we have shared in the past, we have strategically reinvested the COVID-related returns over the past two years, which has helped to ensure we have the necessary growth levers in place to enable the future growth we are forecasting. We will continue taking the action to keep us on a path of success. Slide 8 provides a schematic timelines of substantial non-COVID related capacity we put in place during the last few years, including the new capacity that we expect to activate as fiscal 2023 continues to unfold. As you can see, some of these growth drivers date back years, including our entry into cell therapy in February 2020, which was not expected to contribute meaningful revenue in its few years of ownership as we scale the business through internal investment and tactical M&A, including for iPSCs and plasmids. We now have the right assets in place to drive future earnings growth through these new modalities. Other large expected contributors to our growth have been our organic investment to enhance our BWI gene therapy assets. A year ago, we brought online six additional suites to bring the site's total to 10 suites, and now are running at high utilization rates. In addition, we are now opening a new building on the same campus containing eight more suites, which will progressively come online over the next 12 months as our clients' pipeline progress. Some of the other key investments we have made over the last few years include the drug products range capacity that led to recent tech transfer wins. Investments in additional single-use drug substance production capacity and our entry into the gummy nutritional supplement market just over a year ago, among others. Layering on top of our organic growth drivers is the acquisition of Metrics Contract Services, which we closed on October third. It is now accounted for in our updated guidance. This acquisition is just beginning to enable us to accelerate our existing plans to meet the increasing demand for large-scale high-potency drug manufacturing. Underlying the growth in this business is the increasing number of potent compounds in the oral solids market, particularly in the oral oncology pipeline. Adding potent handling capabilities in large-scale capacity through Metrics represents a continuation of our strategy to maintain a balanced portfolio of offerings that closely matches the overall industry R&D pipeline, which includes a growing number of innovative small molecules that are complex to formulate or require specialized handling. Having explained why we continue to project solid, long-term growth for Catalent, I will briefly highlight factors that have led us to a more conservative orientation towards fiscal 2023 and the decision to adjust our guidance for the year, including changes to the market conditions since our last call and some updated outlooks received from customers, as well as other macroeconomic and sector-specific factors. The macro factors include the further deterioration of the overall economic landscape, particularly in Europe, with increased likelihood of a recession and further tightening of capital markets. We're also beginning to see and anticipate further ripple effects from either inflation, which is impacting consumer confidence and discretionary spending. We're now seeing signs of lower end market demand for nutritional supplements. In addition, we are experiencing delays in the delivery of the new gummy manufacturing lines due to shortages of key components at our European suppliers. We have therefore adjusted our near-term growth assumptions for our consumer health offerings within our pharma and consumer health segment. While our biopharma and consumer health pipelines remain robust, we are starting to experience signs of cash-sensitive decisions by some of our customers. This is most evident in relationship to inventory levels for finished goods or the prioritization of their candidates as they progress through the pipeline. Our adjusted forecast also reflects these new trends. Finally, after several years of elevated levels of capital expenditures, we have made the fiscally prudent decision to rephase some of our CapEx spending planned for this year to maximize utilization, increase free cash flow, and reload our balance sheet. Some of the capacity we initially factored into our initial fiscal 2023 guidance will now be delayed into fiscal 2024, but this rephasing will not impact our long-term growth targets. To respond to the urgent patient demand for vaccines and therapies during the pandemic, we significantly increased our direct and indirect cost base for the past two years, negatively impacting our operating efficiency. Given the new conservative approach, the management team has been working diligently on plans to optimize the cost structure of the organization and recover our historical productivity levels. Many of these actions are already in flight, and all are expected to be operationalized by the end of this calendar year. This is also reflected in the revised guidance. While we are taking the prudent step of adjusting guidance as we navigate the exit from the pandemic, I want to be clear that our underlying business still displays signs of significant areas of strength. As some examples, we continue to forecast strong growth for our overall non-COVID business. Our Zydis business continue its historic record performance. Our gene therapy business has proven out the thesis we lay out when we initially acquired Paragon Bioservices, and our overall funnel of new non-COVID opportunities is at a record high. Shifting gears, I would like to address the FDA audits over the summer that led to Form 483 observations. Quality and compliance are central to everything we do, and we invest constantly to assure the strength of our quality systems and the quality of our operations, and that quality is constantly audited. In fiscal 2022, our facility was subject to approximately 750 inspections, including more than 50 from FDA and other drug regulators around the world, as well as hundreds of customer audits and audits by our own independently managed internal audit staff and their outside consultants. Regulators' inspections occur routinely, and all of us, regulators, customers, and Catalent, are all working to assure that patients receive timely, safe, efficacious, and quality medicines and vaccines. We did so routinely despite the challenges of the pandemic as we provided vaccines to many millions of people around the world, and we will continue to do so. With that said, the regulatory compliance landscape is always evolving, including what is considered best practice. We take all observations we receive seriously and respond to them in a holistic and complete way. We believe that our responses by our Bloomington and Brussels teams will comprehensively address the recent FDA observations, and they've already deployed all necessary resources to implement the changes to which we are committed in a timely manner. To close this topic, and I want to highlight these, while there are some near-term negative P&L effects as we address these observations, the overall related litigation costs are not a notable factor in our revised full-year outlook. To close my remarks, we continue to be excited about the breadth of our offering and their ability to meet customer needs, which will deliver meaningful growth even in a less favorable macroeconomic environment. With the sharp drop in COVID-19 vaccine demand, we pivoted to alternative future growth drivers early in the pandemic cycle and are starting to see the fruits of those investments. We remain deeply focused on executing our mission to develop, manufacture, and supply products that help people live better and healthier lives while enhancing value for our shareholders. Now, I would like to turn the call over to Tom. Thanks, Alessandro. I'll begin this morning with a discussion on segment performance, where commentary around segment growth will be in constant currency. This is the Q1 we are reporting under our new segment structure announced back in July. In both our Q1 earnings release and slide presentation, we are providing historical revenue and EBITDA results that have been recasted as if these segments had been in place for fiscal 2021 and 2022. I will start on slide 9 with the Biologics segment. Biologics net revenue in Q1 of $523 million decreased 2% compared to the Q1 of 2022. The decline is primarily the result of a settlement of take-or-pay contracts for a COVID vaccine that was not considered revenue in the quarter but was previously expected to. We will offset the negative impact later in the fiscal year, likely in the Q2, following the completion of an outstanding poor performance obligation for the client. If we were to include this amount as revenue in Q1, we would have seen growth year-over-year, fueled organically by strong demand for our non-COVID programs, particularly our cell and gene therapy offerings. This strong demand more than offset the decrease in revenue from COVID-related programs. The segment's EBITDA margin of 21.5% was lower by nearly 900 basis points year-over-year from the 30.4% recorded in the Q1 of fiscal 2022. Year-over-year margin primarily contracted due to the underutilized capacity. Other factors included the remediation activity in Brussels, which is ongoing, as well as the negative carry related to the Princeton and Oxford facilities. As shown on slide 10, our Pharma and Consumer Health segment generated net revenue of $499 million, an increase of 11% compared to the Q1 of fiscal 2022, with segment EBITDA increasing 20% over the same period last fiscal year. Both top and bottom line growth were driven inorganically from the acquisition of the Bettera business. Bettera contributed 10 percentage points to PCH's net revenue growth and 12 percentage points to segment EBITDA growth during the quarter. As a reminder, starting in Q2, Bettera will be considered organic. The organic PCH business did see modest revenue growth driven by our wide variety of development offerings, including clinical development supply. Partial offsets to growth came from a decline in prescription drug products and the mandatory closure of our largest PCH site located on Florida's West Coast due to Hurricane Ian. The site was closed for four days but did not withstand any structural damage. Moving to our consolidated adjusted EBITDA on slide 11, our Q1 adjusted EBITDA decreased 26% to $187 million or 18.3% of net revenue. On a constant currency basis, our Q1 adjusted EBITDA declined 24% compared to the Q1 of the prior year, due primarily to the year-over-year decline in COVID-related activity. As shown on slide 12, Q1 adjusted net income was $61 million, or $0.34 per diluted share, compared to adjusted net income of $128 million or $0.71 per diluted share in the Q1 a year ago. Note that our income tax rate was higher in the Q1 than our full year expectation because of the front-loaded weighting in higher tax jurisdictions, which we expect to normalize over the remainder of the fiscal year. Slide 13 shows our debt, related ratios, and capital allocation priorities. Catalent's net leverage ratio as of June 30th, 2022 was 3.2x, slightly above our long-term target of 3.0x. On a pro forma basis, for which we assume the Metrics acquisition closed on September 30th, 2022, as opposed to October 3rd, 2022, Catalent's net leverage ratio would have been 3.6x. This compares to net leverage of 2.9x on June 30th, 2022, and 2.1x on September 30th, 2021. Our combined balance of cash equivalents, and marketable securities as of September 30th, 2022, was $345 million compared to $538 million as of June 30th, 2022. Note that free cash flow still remains negatively impacted by our strategic decision to hold increased inventory levels. When we feel the time is appropriate and are more comfortable with the stabilization of our supply chain, we will begin to reverse course. As of September 30th, 2022, our contract asset balance was $461 million, an increase of $20 million compared to June 30th, 2022. The overwhelming majority of this increase is related to some notably large development programs, particularly within our biologics segment, where revenue is recorded based on a percentage of completion versus entirely on batch release as it is for commercial programs. This difference in approach affects when we are able to invoice customers, thereby delaying cash realization and negatively affecting free cash flow. The expectation, however, is that this figure will decrease throughout the fiscal year as we make progress in shortening the cycle time. As a final point regarding our free cash flow, I note that the decrease in contract liabilities also had a negative impact. Our contract liabilities arise predominantly within our biologics segment and are linked to upfront cash proceeds related to our gene therapy programs. As these programs mature and the performance obligations are met, these balances will shift to recognized revenue, and we have already seen this play out with several large gene therapy customers over the last several quarters. Moving on to capital expenditures. We now expect our fiscal 2023 CapEx as a percentage of revenue to be between 10% and 11%, down from our previous projection of 13%-15%. This moderated rate of CapEx spend and overall more prudent approach to capital deployment as we navigate through a challenging macroeconomic environment better positions Catalent for free cash flow generation. As we have previously shared, we accelerated several planned initiatives to address the pandemic and build capabilities for new modalities sooner. This has put the company today in a position to leverage these new assets and capabilities earlier than anticipated and lead to continued strong non-COVID revenue growth. Now we turn to our adjusted financial outlook for fiscal 2023, as outlined on slide 14. This new outlook assumes the challenging macroeconomic environment will persist longer than originally expected back in August, which justifies a more conservative orientation. It also reflects our acquisitions of Metrics which closed just after the end of the Q1. We now expect full year net revenue in the range of $4.625 billion-$4.875 billion, representing a range of 4% decline at the low end and 1% increase at the high end on an as-reported basis compared to fiscal 2022. FX continues to be a headwind, with an incremental impact of approximately 1 percentage point on both revenue and adjusted EBITDA versus our previous guidance. As a reminder, the guidance we announced in August already included a negative FX impact of approximately 3-4 percentage points on our revenue and adjusted EBITDA growth. After taking into account these considerations, a revised expected organic constant currency net revenue growth rate in fiscal 2023 is expected to be essentially flat at the midpoint of the guidance range. For full year adjusted EBITDA, we now expect a range of $1.22-$1.3 billion, representing a decline of 5% at the low end of the range and an increase of 1% at the high end of the range compared to fiscal 2022. You are familiar with the seasonal nature of our business, where revenue and EBITDA generation are each more weighted to the back half of the year, which has historically led to approximately 60% of our EBITDA to be realized in that period. In fiscal 2023, because we just started the implementation of our cost efficiency activities, we now expect adjusted EBITDA to be even more weighted to the back half of the year at approximately 63%-64%. This also accounts for the much more pronounced year-on-year decline of COVID-related revenue we expect in the Q2 versus the Q1. There are a number of factors that continue to negatively impact margins in fiscal 2023 that we reviewed last quarter, but that will be partly offset by our cost-saving actions. The factors include headwinds from COVID-related volume declines, inflationary and supply chain pressures, startup costs related to our acquisitions of Princeton and Oxford, which we are absorbing in our organic assumptions, other pockets of underutilization across the network as we bring on additional capacity, and foreign exchange translations as our margin profile is higher outside of the U.S., while the majority of our corporate costs are domestic. Note that swings in the euro have a greater impact on FX translation than the pound. Moving to adjusted net income. We now expect full year ANI of $567 million-$648 million, representing a range from a decline of 18% to a decline of 7% on an as-reported basis compared to fiscal 2022. The ANI decline we foresee for fiscal 2023 is being driven by several items. First, the inclusion of the new debt used to fund the Metrics acquisition, which closed in October. Second, servicing the full year of the new variable debt we raised in part to fund the Bettera acquisition, as well as other interest-related increases in the current rising interest rate environment. Next, our expectations for our full fiscal 2023 tax rate remain unchanged from prior guidance. As a reminder, we'll experience a higher effective tax rate in the 24%-25% range compared to the 23.4% we saw in fiscal 2022 due to the geographic mix of earnings. Finally, increased depreciation expense due to our significantly larger asset base, which is also more heavily weighted towards the U.S. We continue to expect our share count to be in the range of 181-183 million shares. Operator, this concludes our prepared remarks, and we'd now like to open the call for questions. Thank you. If you want to ask a question, please press Star followed by one on your telephone keypad. If you wish to remove your question, please press Star followed by two. We'll briefly pause while questions are now being registered. Our first question comes from the line of Luke Sergott of Barclays. Luke, please go ahead. Luke, please kindly unmute your line, and please proceed with your question. Sorry, operator. Let's move to the next question. Of course. Our next question comes from Tejas Savant of Morgan Stanley. Tejas, please go ahead. Hey, guys. Good morning, and appreciate the time here. Perhaps, Alessandro and Tom, just to kick things off on the guide, can you help us just build a bridge between the old and the new outlook at the midpoint? It sounds like you trimmed your top line by about $350 million and EBITDA by $90 million. I'm assuming the COVID payment should have no impact, and the Hurricane Ian impact, I'm assuming, can also be recaptured down the road. Was just curious in terms of, you know, what are your new growth assumptions that you're embedding for non-COVID biologics as well as the PCH segment growth in addition to the Metrics deal? Thanks, Tejas, for the question. Alessandro here. I will cover quickly part of it, and then I'll hand over to Tom. Look, as you see in the Q1, we recorded a non-COVID growth as we expected in the range of 20%+. We expect this to continue through the year. Tom, would you like to go to give a little bit more details? Sure. So good question, Tejas. Related to the guidance, I think your assumptions related to both the timing of the revenue recognition item as well as the hurricane are not impactful in terms of the full year guidance. Both of those, we view as timing related. The macroeconomic backdrop and the worsening conditions we're seeing there are much more of the driver here of the call down. I would say as we look at consumer confidence and discretionary spend and the impacts we're seeing there related to our consumer health business, I would say that's probably 25%-35% of the call down related to those items. I would say that the cash sensitive decisions that we're seeing from some of our customers is not only related to biologic-related customers. We're seeing that on the pharma and consumer health side as well, especially as it pertains to levels of safety stock, inventory that customers are willing to hold at this point in time as they take what we view as a more cash preservation approach to managing their overall supply chain. As well as, you know, how they're thinking about the prioritization of some of the candidates that they have in their pipeline, as well as the timing and the progression of those. Those are, I would say, the larger factors that we continue to see here. Your comments also around Metrics, that acquisition did close in October. That is included in our guidance now as well as the further strengthening of the U.S. dollars that we're seeing here. Those two things I would say nearly offset, maybe not quite, not quite exactly, but they are directionally in the same approach. You know, the macroeconomic landscape obviously has just given us a much more conservative orientation to look at the remainder of the fiscal year. Got it. That's super helpful. As a sort of an unrelated follow-up. Alessandro, two questions, one on the quality front and one on your CapEx decision to trim the spending outlook here. On the quality front, you know, you noted that both Brussels and Bloomington are now operational. Can you just share any update, you know, particularly in terms of your you know, your confidence in you know, your ability to ramp manufacturing for customers at the site, irrespective of what happens with you know, some of these Form 483 you know, letters that you've received and the activities you're taking to address them? As well as any sort of customer conversations around future projects. Has any of this noise had any impact on that? Second, on CapEx, with the decision to pull back CapEx here a little bit given the macro, can you just talk to us about your ability to continue to meet demand, at least over the near term, given the push out to fiscal 2024? Yeah, sure. Look, on the first question, I would say that, you know, what we provided during the prepared remarks is pretty comprehensive in terms of describing the status there. I wouldn't add any more color to that because I believe that it's pretty comprehensive. For sure there are, you know, we continue to keep a fully transparent approach with our customers and sharing with them updates. At this point in time, as we said, we are confident that our responses so far are addressing the observation as expected. With regard to your question on CapEx, that's a very good question. Look, the reality when you go to slide 8 of our presentation, that slide really illustrates what we have already done or what we have in flight. As you would recall, in one of the conversations you and I had a few weeks ago, I did tell you that, you know, we were in the mode of making sure that we had excess capacity across the board to make sure that, you know, there was never the concern of not having enough capacity. I believe given the current macroeconomic environment, we decided that, you know, our assessment is the capacity that we have is more than enough for the runway that we have in front of us for the next several quarters. There will be plenty of time as we detail the CapEx more in fiscal 2024 to be in the same very position to continue to drive long-term growth. That is really not affecting our long-term outlook here. I'll just add, Tejas, in the near term, the only two CapEx projects that we have that, I would say would have an impact on our fiscal 2023 year decision to delay both, related to Oxford, and Princeton, those are now expected to come online during fiscal 2024 and contribute revenue in that period versus in the current fiscal year. Very helpful. Appreciate the color, guys. Thank you. Thank you. Our next question is from Sean Dodge, from RBC Capital Markets. Sean, your line is open. Please go ahead. Good morning. Maybe just staying on the guidance for a moment. The changes there from the cash-sensitive decisions you're seeing from some customers. Just to clarify, is that something you're seeing in Europe only, or is that happening in the United States too? And then Tom, you said happening both on biologics and the PCH side. Is there any more context you can give us there? Does smaller clients making these decisions or larger ones too? And then maybe any more kind of pockets or characterization you can give us of the cash-sensitive decisions? Yeah, Sean, I would say this is not just a dynamic we're seeing in Europe. We're seeing it across both, I would say our European and US-based customers. I did say that this is a dynamic that is crossing both our pharma and consumer health and biologic segments. I would say on the pharma and consumer health side, it's more related to commercial products and consumer health products. I think it's really driven by cash decisions I believe that our customers are making in terms of how they're managing their supply chain. It's not just tied to smaller customers either. I mean, I think, you know, our approach as a large company in terms of looking at things from a more conservative cash flow position is exactly what we're seeing from some of our customers do as well as they look to manage working capital and supply chain in this macroeconomic backdrop. Much more across the board, both large and small customers and also across biologics and the pharma and consumer health. The only other thing I'll add is related to the, you know, examination of their pipeline and progression of their product pipeline and some of the slowdown we're seeing there. That's more attributable to the biologics side of the business. But again, I wouldn't say it's only tied to smaller customers. We're seeing some larger customers that may not be in phase three, but in you know more earlier phase one and phase two programs, just looking to slow play them as they navigate through the macroeconomic environment. Okay. Just thinking about some of the factors that give you visibility on this new guidance. If we go back to the tech transfers you all talked about before, is there anything else you can share that give us some sense of how meaningful those should be in aggregate to the year, maybe like the incremental contribution or revenue from those? Does that cover a quarter of what you need to hit the new guidance, or is it more or less than that? There's been no change, I would say, with regards to the assumptions around those tech transfer programs. They continue to be a meaningful contributor to us in the fiscal year. There are several of those that will be ramping on through the fiscal year here. So, you know, we're not gonna quantify those, Sean, in terms of what their contributions. You know, we don't talk about individual customers or products. You know, I would just say that that continues to be a driver of improved capacity utilization as well as revenue growth as we get into the second half of the year. Yeah. I would add, look, when you look at the drivers that give us conviction about the non-COVID growth, pointing to this tech transfer, but also gene therapy, which was a strong contributor to our performance in Q1. We continue to see to have a good visibility into the trends in these areas of the business. The visibility on these assets to continue to perform is good. Okay, great. Thanks again. Thank you. Our next question is from David Windley, from Jefferies. Dave, your line is open. Please go ahead. Hi. Thanks. Good morning. Thanks for taking my questions. My first question is kind of similar to one of Sean's around revenue mix. I'm wondering if you could, I'm trying to get a better understanding of the relative balance of the impact of the items that you're calling out that drive the reduced guidance across biologics and PCH. It kinda sounds to me like maybe more of it is PCH leaning than biologics, but I don't wanna over assume there. Could you give us some help? Sure, Dave. So I would say it's the de-risking approach we've taken and the more conservative approach we've taken to guidance here really spans both PCH, as well as our biologics segment. I wouldn't necessarily say it's overly weighted towards the PCH side of the segment. I think where we're seeing the bulk of the impact to PCH is related to the consumer confidence discretionary spend, given the macroeconomic inflationary environment that we're seeing, that has a more immediate impact, particularly on the pharma, sorry, on the consumer health side of the business, you know, the gummies business, but also just, I would say the softgel business associated with OTC and consumer products. I mentioned in one of my earlier responses to, I think it was Tejas, about 25%-35%, I would say, of the revenue call down was related to that consumer confidence or consumer spend dynamic that again is more impactful around the PCH side of the segment. The remainder, though, is really just in terms of positioning of our customers across both, you know, large, the biologics side as well as the PCH side, and their cash-sensitive decisions and just a slowdown in overall pace around new programs that we're seeing again on the PCH and biologics side. It's, you know, it's part of that is on the PCH side. I'd... Again, that in addition to the consumer spend gets you to probably a little less than half of the impact being on the PCH side of the business and the rest of it being on the large molecule side. Super. That's helpful. Thank you. If I then focus in biologics, I'm wondering if you might help us to understand how the relative modality growth within biologics is driving that business. You've called out gene therapy a couple times in your prepared remarks and answers. I guess I'm just wondering, like the tech transfers, have you shared with us that those are specifically in sterile fill finish or not? As we think about kind of the mix of your biologic modalities in 2023 versus 2022, does that change materially? I would say it doesn't change materially, Dave. We have said that the tech transfer programs are going to be meaningful contributors in the second half growth in part of the Q2, but into the second half growth as they really start to ramp. We have said that those are drug products related and tied to our sterile fill finish assets on past quarters. The comments we made around the Q1 and some of the growth that we've seen on the gene therapy and cell therapy side is expected to continue. That is a business that saw strong performance in the Q1 will throughout the fiscal year as well. Look, you know, Alessandro here, I will tell you that we need to, you know, clearly here it's very important that we make evaluations on an all-in basis and a non-COVID basis, clearly because biologics is surely the segment that is most impacted by the COVID volume reduction, as you all know, and particularly the fill and finish side of the business. I will tell you though that across all the modalities, when you look at them and the prospects of growth ex-COVID on all of them, we are pretty excited about the dynamic there, even after our more conservative approach to guidance, which is reflecting some macro factors which led us to be having a more conservative orientation here. Even with that conservative orientation, we feel very, very excited about the opportunities we see in gene therapies, you know, the expected tipping point for other and also in the tech transfer. In biologics it's, you know, on an ex-COVID basis, we continue to be excited. Excellent. That's helpful. My last question is around, kind of general margin bridge, I guess goes back to Tejas' question a little bit, but you're taking revenue down, as you said, more conservative. We would normally expect some, you know, decrementals in a high fixed cost business, so that is a baseline expectation. You also have remediation costs related to the quality issues that you raised in your remarks, you know, inflation and other things that are, you know, that are challenges. It, you know, your margin forecast for the new guidance is essentially the same as the old guidance. I'm looking for help on the cost levers that you're able to pull to mitigate the decremental on the revenue drawdown. Yeah. No, well, good question, Dave. Look, I think our margins are looking to be flat this current year in the new guidance in comparison to where they were in the prior year. The cost savings initiatives that we have underway that we've already started to take action all of those will be operationalized by the end of the calendar year so we'll be seeing full impacts in the second half of the year related to those. I think the dynamic that we're seeing around the underutilization is certainly playing into the margin situation here in the quarter, as is the material piece of the business when we think about the component sourcing side of things. The startup costs also related to Princeton and Oxford ramping up, also margin dilutive in the period. The cost actions that we have underway running the business in a much more efficient way, looking at things from a spans and layers standpoint in terms of how we operationalize our large sites are meaningful cost savings actions that we have the ability to utilize here and leverage that we absolutely are pulling. Okay. Great. Thank you. Thank you. Our next question is from Julia Kim from JP Morgan. Julia, your line is open. Please go ahead. Hi. Morning. This is Amy on for Julia. Thank you for taking our question. I have a follow-up on the CapEx, the slowdown of the CapEx. Could you tell me a little bit more, which capacity or areas that you guys are cutting down? Like, is this a reflection of, financial prudence or are you concerned about, overcapacity? The topic related to that is, can you also add more colors on the push out of the Princeton and Oxford plants into 2024? Well, sure. Look, I wouldn't call necessarily these cuts in our spend. You know, as we said, this is a rephasing. It's a different timing in which we're gonna bring online this capacity. Clearly, our job as CDMOs is always to keep our utilization rates at reasonable levels to continue to drive margin and as such, cash flow. This is a combination of when you look at how much we have brought online, which is on slide 8, which is a very exciting picture, if you like, in terms of how much we have brought online, which is not COVID related, and how many levers we have to continue to drive growth in the industry in areas that continue to be very exciting from a pipeline standpoint. We feel pretty good about what we have already built. Looking into the future, given our more conservative approach to guidance, we thought it was prudent to slow down a little bit the additional capacity coming online so that we could keep the level of absorption as expected, but also not jeopardizing the long-term growth prospects of the company. These all, you know, you know, result in a fiscally prudent approach, which I believe, given the environment, is the right thing to do. Thank you. I have one question, and then we'll hop off. Can you share some visibility about the non-COVID based business ramp into 2023 under the new guidance, especially in the biologic sectors? Like what percentage of the revenue will come from customers that stick around after you know COVID? And what support your confidence into the rest of the year, the second half of the year? Thanks. Look, we're very pleased with the start we had fiscal 2021 here on a non-COVID basis. We mentioned in Alessandro's prepared remarks, as well as mine, that we saw more than 20% growth across the company on a non-COVID basis in the Q1. Our guidance assumes we continue to see growth around those levels. We haven't disclosed what the split out will be between the pharma and consumer health side of the business versus that of the biologics side of the business. Many of the growth drivers we have are related to modalities that were not impacted by COVID related volumes. Just think about the cell and gene therapy strength that we saw in the Q1, and that the expectations that continues here into the second half of the fiscal year. Again, we're just really looking at things to continue to trend on a non-COVID basis, in line with what we saw in the Q1, in the more conservative view of our guidance that we presented today. Thank you. Thank you. Our next question is from Derik De Bruin from Bank of America. Derik, please go ahead. Your line is open. Hi. Good morning. I've got a few here. Can you just elaborate a little bit more on what you mean by the slowdown in pacing for starting programs? I would assume it's not still finished. Is it more drug substance? And then on the consumer side, just what you're saying, just a little bit more color around what exactly and where it's being impacted. Derik, I would say it's really very widespread. I mean, we're seeing it, as I mentioned, not only in the biologic side of the business, but on the pharma and consumer health side. We're seeing it across both commercial products, where customers are willing to appear to manage the supply chain to a more conservative level here and not run on the same levels of inventory here as they look to manage working capital. But I would say that the pace is more around some of the development programs that we have now. You know, phase three programs that are full blown into clinical trial activity are not the types of programs that we're talking about here. You know, we have plenty of programs across the network, both on the biologics and PCH side, in development that I would say in that phase two range, where we are seeing maybe some tempered expectations in terms of the pace in which customers are moving through there as they look to, you know, potentially manage their cash situation. Again, going back to comments I made earlier, really across both pharma and consumer health and, you know, against the commercial products and development side of things. Just a more conservative approach to guidance from our standpoint was necessary based on some of these trends we're seeing across the customer base. Okay. A couple of just housekeeping questions. What is, given the new debt and the increased interest rates, your expectation for net interest expense for the year? You know, how big is your macro sensitive, what you would consider macro sensitive? Sure. Portion of business, particularly on site? The slide in the deck has a good view of the capital structure, Derek, for you to take a look at. I would say, you know, about 25% of our debt, when you take into consideration the debt that's been borrowed on the revolver to fund the Metrics acquisition is floating and more tied to the rising interest rate environment with about 75% of that being considered fixed. Hopefully that can be helpful as you look to model this. Okay. Do you feel like you've appropriately de-risked the COVID exposure enough for this year? I would say there's been very little change to our assumptions around COVID, just given the contractual obligations that we have here. Much more of the call down was related to non-COVID business and the macroeconomic environment that we're in here. Nothing else to note around the COVID side of things. Okay. Thank you. Thank you. Our next question is from Max Smock from William Blair. Max, your line is open. Please go ahead. Hi. Thanks for taking our questions. Just the first one for me here. You've called out a number of factors really behind the reduced guide for this year, but one of the things we haven't touched on is the ability for you to change over from COVID to non-COVID work and whether or not that factored into the results in the quarter as well as your outlook for the year. So just trying to get a sense for, you know, whether or not this transition has maybe been a little harder than you expected or it's part of the issue here, or if you've been able to kind of make that shift in line with your expectations. No, look, you know, Alessandro here. Look, as we said multiple times, most of the non-COVID work is executed on assets which are unrelated to the COVID execution. The two things don't tend to interfere with each other. As we have said, you know, even the settlement released into the quarter was something that was somewhat planned for. Given our approach that we shared multiple times, that our approach is holistic and looking at the partnership with important customers which have, you know, much more than just a COVID relationship with us. I wouldn't say that, you know, this has had any interference with our ability to execute on the non-COVID work. Look, I always go back to the point that, you know, in our Q1, we were able to deliver a non-COVID growth of 20%+, which is a remarkable performance. Got it. Yeah, that's helpful. As a follow-up, I mean, one of the things you mentioned last quarter was that non-COVID growth benefited a little bit from some backlog going through the system related to some projects that, you know, maybe had suffered a little bit as you prioritize COVID. Just wondering if there's any way to quantify whether or not this had an impact in the quarter. If so, is the backlog now largely worked through, or should we expect this kind of to be a somewhat of a tailwind, I guess, for the business throughout fiscal 2023? Well, there are some areas where we continue to be a little bit capacity constrained when you look at the demand. I would say that overall the backlog in terms of demand that we need to still clear out has not changed dramatically in terms of the picture. There are maybe some areas of the business where we're seeing even more success than what we anticipated in terms of demand. Like, I named Zydis as one notable item in our business where we are trying to build additional capacity at speed. I would say with all the backlog situation has not changed dramatically. Got it. I'll leave it it. I'll leave it there. Thank you. Thank you. Before our next questioner, I would just like to kindly ask everyone if they could limit themselves to one question to allow everyone the chance. Our next questioner is Justin Bowers from Deutsche Bank. Justin, please go ahead. Your line is open. Hey, good morning. Just on the settlement you described, is that a good kind of quarterly run rate that we should assume with the exception of kind of like the true-up that you're gonna have in 2Q? Then the comments on reduced utilization, is that you know how does that split between biologics and PCH? It seems like it's more weighted to PCH. Then on PCH, what's kind of like lead time for lots of discretionary? I'll stop there. Thank you. Just to take your comment, Justin, around the timing of COVID related to the settlement. There's no quarterly phasing here that I would read into the recognition related to this in terms of run rate. This was a settlement related to one customer. As you know, there are two major customers in which we, you know, have COVID-related volumes for here. I will say the comments I made are that the COVID-related headwind that we see during fiscal 2023 is going to be more pronounced in the Q2 than it was in the Q1, and I would say it will be, you know, equally as pronounced in the third quarter. Our second and third quarters are the quarters in which we're most expected to see COVID-related volume declines as we head through the fiscal year. In terms of the comment related to capacity utilization, I would say as you look at the slide in the materials here in slide 8 where we talk about new capacity that has come online or is in the process of coming online, many of those are biologics-related assets. The assumption that some of the underutilization and capacity that we're going to see in fiscal 23, which we've alluded to before, given the timing of bringing on this new capacity as well as the ramping associated with starting to fill that is much more of a biologics dynamic than it is a pharma and consumer health dynamic. Okay. Next question, please. Thank you. Our next question is from Jacob Johnson from Stephens. Jacob, your line is open. Please go ahead. Good morning, everyone. This is Mack on for Jacob. Just a quick question from me. As it relates to your cell and gene therapy business, I think you have at least one commercial customer and another potentially coming. How should we think about the size of a given commercial cell and gene therapy customer? Or looking at it in another way, what is the potential revenue capacity of a suite at BWI? you can't look at the suites at BWI on a you know revenue basis. No programs are equal. There's a lot of different things I would say that factor into how you would look at the potential revenue here. I think your comments are spot on. We have had a commercially approved program. We have several programs that I would say are in later stage. I think you're probably referring to one specific. Look, I think that continues to be a meaningful customer for us. It's assumed in our guidance in fiscal 2023 that it will continue to be, and it's difficult to comment on any specific customer or individual programs as well as the revenue I would say attached to it. The progress of the pipeline that we have within gene therapy, the fact that, you know, we've been investing here to bring on additional suites, which we'll have 18 suites here as we get through fiscal 2023 up and running, as well as 150 different development programs that we have on the gene therapy side of the business here. A very robust pipeline that continues to mature. I agree with that. From the more helicopter view, we believe that our BWI asset with the gene suite will be one of the largest, if not the largest, viral vector manufacturing assets out there. That clearly is gonna be a meaningful contributor to our growth story in the next few years, given also the strength of the pipeline that we're seeing with the customers progressing to late stage and potential approval. All right. Next question, operator. Thank you. Our next question is from John Sourbeer from UBS. John, your line is open. Please go ahead. Thanks for taking the question. You know, maybe just one here and some of the comments you mentioned on the inflationary pressures that in the updated guide. You know, can you talk a little bit just on pricing and, you know, are you starting to see now more pushback from customers, maybe being more specific on biotech customers on some of the price increases with the inflationary pressures in the market? Thanks. Yeah, sure. Look, I do believe that we have been successful in leveraging the price as appropriate. Clearly, it's not a one-size-fits-all around the different offerings. There are different market positions. Clearly on your more commercial business where you have long-standing contracts and there are mechanisms and relationships and so forth, it tends to be, you know, easier and more aggressive stance. In the other places where, you know, you are competing to win business, you really need to be careful around where the market is going. We have a very good pulse of what are the areas of opportunities, and we are doing everything we can on every opportunity there to make sure that we offset as much as we can at the inflationary pressure that we are seeing. All right. Thank you. Next question, Daisy. Our next question is from Jack Meehan from Nephron Research. Jack, your line is open. Please go ahead. Good morning. Alessandro or Tom, can you provide color on cancellations? How were they in the quarter relative to historical periods? Look, I wouldn't say we've seen much in the way of cancellations in the current quarter here. That wasn't an impact of the results in Q1. I would say we've seen a handful of cancellations as we think about the remainder of the fiscal year, but I wouldn't necessarily say it's any different than what we're seeing than what we've seen historically. I would say, though, the overall progression of not things that are being canceled, but just the pace in which customers are willing to move is where we're seeing the slowdown, right? This isn't programs that are being necessarily canceled, but certainly a slowdown. That slowdown, both on the pharma and consumer health side as well as the biologic side, was what was contemplated in the more conservative view of the guidance. Yeah, look, I would call it more selectivity, right? Selectivity on both sides, our side, the customer side, in terms of understanding how we're gonna progress the business going forward given the cash situation. Thank you. Our next question is from Evan Stover from Baird. Evan, your line is open. Please go ahead. Yeah. I wanna make sure I understand how consumer spending habits actually impact your business. Earlier in the question and answer, you said that the change in consumer spending was about 30% of the guidance cut, or you know, my math, that's about $100 million. Also, if I look at what that would relate to, your consumer health and OTC business is about a $700 million business in fiscal 2022. I guess $800 million if I fully impact it with Bettera. I mean, I just put those two together and it's a $100 million cut on a $700 million or $800 million business. It's you know, a strong double-digit impact for that business and for a change in consumer spending behavior, which seems like a big change in end market demand. I just wanna make sure I really understand how that consumer spending impacts your business. Well, look, I will refer to Tom more on the specifics. I gotta tell you that you don't have to look at this only on an end market demand standpoint, right? There are at times two compounding effects of one is the end market, and the other one is the stock levels. You know, there are temporary demand. Our demand is the combination of the end demand and how much inventory our customers want to carry about each individual offering. Clearly, when there is more uncertainty and surely the orientation towards the end market demand tends to be a little bit lower, there is surely in a capital tight market as we are running today, there is more a conservative approach, how much inventory you want to carry. These are the inventory piece is a temporary effect that tends to, you know, balance off in a few months period, because at some point, once the destocking is happened, you're really, you know, really serving the end market demand. You know, I believe these are the two effects that compounded, probably explain better the dynamic around your question. Thank you. Our last question today is from Luke Sergott from Barclays. Luke, your line is open. Please go ahead. Great. Thanks for sneaking me in at the end here. Can you guys give us a sense of the guidance methodology and, you know, how you guys factor in potential approvals from some of those cell and gene therapy businesses? Can you give us a sense of or just give us a size of the business of cell and gene therapy and how that's been growing? Sure, Luke, I'll give you some directional color here. Look, we haven't quantified the cell and gene therapy business in terms of its size, but I'll rank our revenue contributors biologics overall here, and I would definitely dissect both cell and gene therapy because they're two very different businesses at different stages of maturity. Our drug product business around biologics is our largest revenue contributor here, but our gene therapy, I would say, is a close second to that in terms of its contributions to the $2.5 billion of biologics revenue that we would have annually. I would say from there, it's our drug substance business and then our cell therapy, and then you start getting into some smaller revenue contributions from plasmid DNA, iPSCs, et cetera, here. Our gene therapy is the number two, you know, contributor to our overall biologics revenue in terms of absolute dollars. It's the area where we're seeing fastest growth right now, for sure, and a big reason of why we saw the growth we did in the Q1 across the company of more than 20% on a non-COVID basis. In terms of assumptions, here, look, we're not going to take an overly aggressive approach to regulatory approvals, which are, you know, outside of our control and in many cases, in most cases, outside of our customers' control as well. You know, we're not assuming any significant impacts from a commercial approval down the road here that factors into us being able to achieve our guidance, especially a guidance that's been built now with a much more conservative orientation than what we have previously had discussed. Maybe I'll add just one comment in terms of adding additional color to the dynamics here. You need to think about the potential commercial approval not only as a dynamic to serve the commercial approval, but there is also a dynamic that precedes that that is a more launch stock build-out, which you do normally for sizable approvals on which we have a little bit more confidence around what the impact could be. With that said, I would like to wrap up the call. I guess we are done with questions. Thanks everyone for taking the time today to join our call and for your continued support of Catalent. Thank you, everybody. Thank you everyone for joining today's call. You may now disconnect your lines and have a lovely day.